| Revenue growth | 6.7% YoY in Q4; -15.6% YoY for full FY26. |
|---|---|
| Margins | Q4 EBITDA margin 4.9% vs -8.1% YoY. FY26 margin 0.11%. |
| Demand visibility | Healthy traction in API existing molecules; Hospital segment focus. |
| Management confidence | High optimism for improving business momentum and operational efficiencies. |
Growth
Q4 revenue grew 6.7% YoY; FY26 revenue ₹342.2cr vs ₹405.5cr in FY25. EBITDA margin improved to 4.9% in Q4.
Outlook
Targeting RoW markets (CIS, GCC) in 0-3 years and regulated markets (EU, USA) in 3-5 years.
Risks
Softness in Formulations segment; high market fragmentation; long lead times for hospital reputation building.
Earnings Call filed with BSE, NSE: THEMISMED. Summary written with AI assistance from the document.
Themis Medicare Ltd: key numbers
- Share price
- ₹116.93
- Market cap
- ₹1,077 Cr
- Revenue (annual)
- ₹342.2 Cr
- Net profit (annual)
- ₹1.14 Cr
- P/E (TTM)
- 26.9×Sector 50.4×
- Promoter holding
- 67.11%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Themis Medicare Ltd
All →Themis Medicare Capital Structure Change
Themis Medicare Ltd withdrew its proposed preferential issue of 45,95,795 warrants. The company secured working capital through alternative means, and no adverse impact is expected.
Themis Medicare Dividend
Themis Medicare fixed the record date as September 23, 2026, for its final dividend FY 2025-26, pending AGM approval on September 30, 2026. No dividend per-share amount is stated.
Themis Medicare Annual General Meeting
Themis Medicare Limited has issued the notice for its upcoming Annual General Meeting scheduled for September 30, 2026. Shareholders will consider resolutions including dividend declaration.
Themis Medicare Annual Report
Themis Medicare Limited has filed its Annual Report for the financial year 2025-26, along with the notice for its 56th Annual General Meeting.
Themis Medicare Price Movement Clarification
Themis Medicare Limited has clarified to the exchange that there is no pending or delayed material information regarding the recent increase in trading volume.
Themis Medicare Investor Presentation: Key Takeaways
Themis Medicare Q1 FY27 revenue hit ₹86.96 Cr with 28.3% PAT margin, significantly boosted by one-off gains of ₹92.95 Cr from share sales.